688796 百奥赛图
盘后交易 01-21 15:00:00
资讯
新帖
简况
港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署
智通财经 · 10:27
港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署
百奥赛图(688796)新增【AI智能体】概念
证券之星 · 01-15
百奥赛图(688796)新增【AI智能体】概念
百奥赛图-B盘中涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署
新浪港股 · 01-14
百奥赛图-B盘中涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署
百奥赛图-B(02315.HK)一度涨超12%
每日经济新闻 · 01-14
百奥赛图-B(02315.HK)一度涨超12%
百奥赛图-B盘中涨超11%再创新高 公司与育世博达成进一步合作
金融界 · 01-13
百奥赛图-B盘中涨超11%再创新高 公司与育世博达成进一步合作
百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目
智通财经 · 01-12
百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目
港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作
智通财经 · 01-12
港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作
国联民生证券:首予百奥赛图(02315)“推荐”评级 基石业务稳增长 抗体平台高弹性
智通财经 · 01-05
国联民生证券:首予百奥赛图(02315)“推荐”评级 基石业务稳增长 抗体平台高弹性
每周股票复盘:百奥赛图(688796)非执行董事魏义良离任
证券之星 · 01-02
每周股票复盘:百奥赛图(688796)非执行董事魏义良离任
百奥赛图(688796)披露公司非执行董事离任公告,12月31日股价上涨2.57%
证券之星 · 2025-12-31
百奥赛图(688796)披露公司非执行董事离任公告,12月31日股价上涨2.57%
百奥赛图:董事魏义良辞任
南方财经网 · 2025-12-31
百奥赛图:董事魏义良辞任
百奥赛图-B盘中涨超5% 华福证券首予“买入”评级
新浪港股 · 2025-12-31
百奥赛图-B盘中涨超5% 华福证券首予“买入”评级
港股异动 | 百奥赛图-B(02315)再涨超5% 公司近期正式进入港股通名单 机构称千鼠万抗开始兑现
智通财经 · 2025-12-31
港股异动 | 百奥赛图-B(02315)再涨超5% 公司近期正式进入港股通名单 机构称千鼠万抗开始兑现
港股异动 | 百奥赛图-B(02315)涨超6%再创新高 公司已正式进入港股通 机构指千鼠万抗前景广阔
智通财经 · 2025-12-29
港股异动 | 百奥赛图-B(02315)涨超6%再创新高 公司已正式进入港股通 机构指千鼠万抗前景广阔
百奥赛图-B(02315)获纳入港股通名单 业绩高增驱动价值重估
智通财经网 · 2025-12-29
百奥赛图-B(02315)获纳入港股通名单 业绩高增驱动价值重估
智通港股解盘 | 晶圆涨价持续助推AI材料端 稀有资源镍矿集体走强
智通财经 · 2025-12-24
智通港股解盘 | 晶圆涨价持续助推AI材料端 稀有资源镍矿集体走强
百奥赛图-B(02315.HK)涨近20%
每日经济新闻 · 2025-12-24
百奥赛图-B(02315.HK)涨近20%
百奥赛图-B获调入港股通标的证券名单,12月24日起生效
老虎资讯综合 · 2025-12-24
百奥赛图-B获调入港股通标的证券名单,12月24日起生效
百奥赛图上市第5个交易日跌10.47%创新低
中国经济网 · 2025-12-16
百奥赛图上市第5个交易日跌10.47%创新低
C百奥(688796)新增【基因】概念
证券之星 · 2025-12-12
C百奥(688796)新增【基因】概念
加载更多
公司概况
公司名称:
百奥赛图(北京)医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2025-12-10
主营业务:
百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。
发行价格:
26.68
{"stockData":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"百奥赛图","latestPrice":65.26,"timestamp":1768978800000,"preClose":63.22,"halted":0,"volume":2637920,"delay":0,"changeRate":0.0323,"floatShares":35887600,"shares":447000000,"eps":0,"marketStatus":"盘后交易","change":2.04,"latestTime":"01-21 15:00:00","open":63.3,"high":67.27,"low":63.3,"amount":173000000,"amplitude":0.0628,"askPrice":65.28,"askSize":5,"bidPrice":65.26,"bidSize":312,"shortable":0,"etf":0,"tradingStatus":3,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769045400000},"marketStatusCode":4,"adr":0,"adjPreClose":63.22,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768959000000,1768966200000],[1768971600000,1768978800000]],"highLimit":69.54,"lowLimit":56.9,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446898420,"isCdr":false,"pbRate":28.95,"roa":"--","roe":"12.61%","epsLYR":0.08,"committee":0.775378,"marketValue":29165000000,"turnoverRate":0.0735,"status":0,"afterMarket":{"amount":0,"volume":0,"close":65.26,"buyVolume":200,"sellVolume":0,"time":1768979328558,"indexStatus":"盘后交易 01-21 15:08:48","preClose":63.22},"hkstockBrief":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":40,"timestamp":1768979222675,"preClose":37.8,"halted":0,"volume":1549000,"delay":0,"premium":"-45.29"},"floatMarketCap":2342000000},"requestUrl":"/m/hq/s/688796","defaultTab":"news","newsList":[{"id":"2605129183","title":"港股异动 | 百奥赛图-B(02315)再涨近7% 公司已完成AI驱动抗体药物研发平台的本地化部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2605129183","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605129183?lang=zh_cn&edition=full","pubTime":"2026-01-21 10:27","pubTimestamp":1768962437,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B(02315)再涨近7%,截至发稿,涨5.08%,报39.72港元,成交额2832.35万港元。消息面上,百奥赛图近日在互动平台表示,公司已完成AI驱动抗体药物研发平台的本地化部署,并实现其与公司核心业务千鼠万抗计划的全面协同。通过AI的本地化部署,公司正在建设抗体药物研发ai智能体。随着千鼠万抗计划与AI系统深度整合的持续推进,公司将为全球药企提供更加高效的研发工具和更为丰富的抗体分子库,帮助药企伙伴提高临床前PCC分子的研发效率,这也将推动抗体发现业务迈入全新发展阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1395442.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","02800","BK1161","BK1610","BK0216","02315"],"gpt_icon":0},{"id":"2603560789","title":"百奥赛图(688796)新增【AI智能体】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2603560789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603560789?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:30","pubTimestamp":1768480219,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,1月15日百奥赛图新增概念。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500037981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159819","688796","BK0216"],"gpt_icon":0},{"id":"2603665720","title":"百奥赛图-B盘中涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署","url":"https://stock-news.laohu8.com/highlight/detail?id=2603665720","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603665720?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:08","pubTimestamp":1768356480,"startTime":"0","endTime":"0","summary":" 百奥赛图-B盘中涨超12%,近三日累涨约30%。截至发稿,股价上涨7.58%,报46港元,成交额5387.96万港元。 1月13日,百奥赛图在互动平台表示,公司已完成AI驱动抗体药物研发平台的本地化部署,并实现其与公司核心业务千鼠万抗计划的全面协同。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-01-14/doc-inhhfrsv5260509.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02315","688796","BK0216","BK1161"],"gpt_icon":0},{"id":"2603650957","title":"百奥赛图-B(02315.HK)一度涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603650957","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603650957?lang=zh_cn&edition=full","pubTime":"2026-01-14 10:03","pubTimestamp":1768356223,"startTime":"0","endTime":"0","summary":"每经AI快讯,百奥赛图-B(02315.HK)一度涨超12%,近三日累涨约30%。截至发稿,百奥赛图-B涨6.74%,报45.64港元,成交额2818万港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143618563076.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143618563076.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","02315","688796","BK1161"],"gpt_icon":0},{"id":"2603571312","title":"百奥赛图-B盘中涨超11%再创新高 公司与育世博达成进一步合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2603571312","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603571312?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:34","pubTimestamp":1768275273,"startTime":"0","endTime":"0","summary":"百奥赛图-B盘中涨超11%,高见44港元,再创历史新高。据悉,该协议将授予育世博一项选择权以获得百奥赛图两项BsADC项目的全球独家许可。百奥赛图将有权获得选择权首付款;在育世博行使相关选择权后,百奥赛图还可获得包括选择权行使费、开发和监管里程碑付款、商业化里程碑付款以及销售分成在内的后续款项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/01/13113455031362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02315","BK1161","BK0216","688796"],"gpt_icon":0},{"id":"2602511720","title":"百奥赛图-B(02315)通过基于选择权的评估框架与育世博达成进一步合作共同推进同类首创双特异性抗体双药物偶联物项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2602511720","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602511720?lang=zh_cn&edition=full","pubTime":"2026-01-12 19:50","pubTimestamp":1768218604,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B 发布公告,近日,公司与育世博股份有限公司(育世博)达成一项选择权与许可协议,旨在通过结构化的评估机制,对双特异性抗体药物偶联物项目开展系统性评估,从而进一步加速双特异性抗体双药物偶联物的开发进程。此前,双方的合作重点聚焦于对有成药潜力的双特异性抗体及双载荷抗体药物偶联物候选项目的评估与筛选。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688796","02315","BK1161"],"gpt_icon":0},{"id":"2602561159","title":"港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2602561159","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602561159?lang=zh_cn&edition=full","pubTime":"2026-01-12 09:43","pubTimestamp":1768182183,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B盘中涨近10%,高见39.46港元创上市新高。该协议将授予育世博一项选择权以获得百奥赛图两项BsADC项目的全球独家许可。百奥赛图将有权获得选择权首付款;在育世博行使相关选择权后,百奥赛图还可获得包括选择权行使费、开发和监管里程碑付款、商业化里程碑付款以及销售分成在内的后续款项。信达证券近日研报指出,整体来看,百奥赛图模式动物销售业务和临床前药理药效评价业务协同发展,目前正处于高速成长期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391407.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","BK1161","688796","02315"],"gpt_icon":0},{"id":"2601079117","title":"国联民生证券:首予百奥赛图(02315)“推荐”评级 基石业务稳增长 抗体平台高弹性","url":"https://stock-news.laohu8.com/highlight/detail?id=2601079117","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601079117?lang=zh_cn&edition=full","pubTime":"2026-01-05 10:31","pubTimestamp":1767580296,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,国联民生证券发布研报称,首次覆盖,给予百奥赛图“推荐”评级,公司三大业务板块行业景气且收入高增,随着“千鼠万抗”计划实现阶段性成果,大规模研发投入进入尾声,募集资金有望大幅缓解财务费用。临床前产品及服务快速增长,抗体平台增长力强,海外加速渗透,25H1收入占比67.9%,全球top20合作客户数量及占比持续增加,客户优质。临床前CRO服务模式动物延伸而来,海外收入占比79%,投融资回暖趋势下高增确定性强。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1388481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","601456","161027","01456","688796"],"gpt_icon":0},{"id":"2600103934","title":"每周股票复盘:百奥赛图(688796)非执行董事魏义良离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2600103934","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600103934?lang=zh_cn&edition=full","pubTime":"2026-01-02 03:52","pubTimestamp":1767297130,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘,百奥赛图报收于50.91元,较上周的50.07元上涨1.68%。本周,百奥赛图12月24日盘中最高价报54.0元。本周关注点公司公告汇总:非执行董事魏义良因工作安排辞任,不影响董事会正常运作公司公告汇总百奥赛图(北京)医药科技股份有限公司董事会近日收到魏义良先生提交的辞职报告,其因其他工作安排原因申请辞去公司董事职务,辞职后不再担任公司任何职务。魏义良先生与董事会无分歧,公司对其任职期间的贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010200001085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2595777624","title":"百奥赛图(688796)披露公司非执行董事离任公告,12月31日股价上涨2.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595777624","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595777624?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:27","pubTimestamp":1767191235,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,百奥赛图报收于52.6元,较前一交易日上涨2.57%,最新总市值为235.07亿元。近日,百奥赛图(北京)医药科技股份有限公司发布公告称,公司董事会近日收到魏义良先生提交的辞职报告,其因其他工作安排原因申请辞去公司董事职务,辞职后不再担任公司任何职务。该辞职不会导致公司董事会成员低于法定人数,不影响公司董事会正常运作,辞职报告自送达董事会之日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"gpt_icon":0},{"id":"2595721372","title":"百奥赛图:董事魏义良辞任","url":"https://stock-news.laohu8.com/highlight/detail?id=2595721372","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595721372?lang=zh_cn&edition=full","pubTime":"2025-12-31 15:40","pubTimestamp":1767166843,"startTime":"0","endTime":"0","summary":"南财智讯12月31日电,百奥赛图公告,公司董事会于近日收到魏义良先生提交的辞职报告。魏义良先生因其他工作安排原因申请辞去公司董事职务。辞职后,魏义良先生不再担任公司任何职务。魏义良先生辞职不会导致公司董事会成员低于法定最低人数,其辞职报告自送达公司董事会之日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512313606940275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2595744212","title":"百奥赛图-B盘中涨超5% 华福证券首予“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2595744212","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595744212?lang=zh_cn&edition=full","pubTime":"2025-12-31 10:12","pubTimestamp":1767147120,"startTime":"0","endTime":"0","summary":" 百奥赛图-B盘中涨超5%,截至发稿,股价上涨3.26%,现报35.50港元,成交额3126.55万港元。 上交所与深交所近日公告,将百奥赛图调入港股通股票名单,自2025年12月24日起生效。 华福证券此前研报指出,公司千鼠万抗开始兑现,抗体授权驱动业绩爆发。考虑公司业务的高成长性及高壁垒,临床前动物及药理药效评价基本盘稳固,抗体开发业务已逐步进入业绩兑现期,叠加潜在的新药管线具有潜力,首予“买入”评级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-12-31/doc-inhesahv5290752.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02315","161027","688796"],"gpt_icon":0},{"id":"2595449417","title":"港股异动 | 百奥赛图-B(02315)再涨超5% 公司近期正式进入港股通名单 机构称千鼠万抗开始兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2595449417","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595449417?lang=zh_cn&edition=full","pubTime":"2025-12-31 10:05","pubTimestamp":1767146749,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B(02315)再涨超5%,截至发稿,涨4.94%,报36.08港元,成交额2758.41万港元。消息面上,上交所与深交所近日公告,将百奥赛图调入港股通股票名单,自2025年12月24日起生效。此举标志着公司构建“A+H”双资本市场平台后的又一重要里程碑,其港股通道自此向内地投资者全面敞开。华福证券此前研报指出,公司千鼠万抗开始兑现,抗体授权驱动业绩爆发。考虑公司业务的高成长性及高壁垒,临床前动物及药理药效评价基本盘稳固,抗体开发业务已逐步进入业绩兑现期,叠加潜在的新药管线具有潜力,首予“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688796","BK0216","02315"],"gpt_icon":0},{"id":"2595270060","title":"港股异动 | 百奥赛图-B(02315)涨超6%再创新高 公司已正式进入港股通 机构指千鼠万抗前景广阔","url":"https://stock-news.laohu8.com/highlight/detail?id=2595270060","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595270060?lang=zh_cn&edition=full","pubTime":"2025-12-29 09:54","pubTimestamp":1766973261,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B早盘涨超6%,高见37.28港元,再创上市新高。消息面上,近日,上交所与深交所公告,将百奥赛图-调入港股通股票名单,自2025年12月24日起生效。银河证券发布研报称,百奥赛图公司以基因编辑技术为基石,随着公司主要投入的千鼠万抗计划进入兑现期,公司业绩有望带来大幅增长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0216","688796","02315"],"gpt_icon":0},{"id":"2595277564","title":"百奥赛图-B(02315)获纳入港股通名单 业绩高增驱动价值重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2595277564","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595277564?lang=zh_cn&edition=full","pubTime":"2025-12-29 08:54","pubTimestamp":1766969651,"startTime":"0","endTime":"0","summary":"近日,上交所与深交所公告,将百奥赛图-B调入港股通股票名单,自2025年12月24日起生效。回顾市场历史,纳入港股通往往是上市公司迎来价值重估的重要契机。凭借稀缺的商业模式、深厚的技术护城河和业绩面近期的显著利好,此次纳入港股通,将有望成为推动百奥赛图投资价值被二次重估的关键催化剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02315","BK1161","BK0216","688796"],"gpt_icon":0},{"id":"2593471013","title":"智通港股解盘 | 晶圆涨价持续助推AI材料端 稀有资源镍矿集体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=2593471013","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593471013?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:51","pubTimestamp":1766577112,"startTime":"0","endTime":"0","summary":"备案文件显示,关税税率将至少提前 30 天公布。据其分析称,AI 服务器等产品电源芯片的大量需求占用 BCD 产能,是此次涨价主要行业因素,“暂不清楚未来其他晶圆厂是否会跟进涨价”。各种 AI 相关材料都在涨价,据报道,三星电子、SK 海力士等存储供应商已上调明年 HBM3E 价格,涨幅接近 20%。数据显示,此次越疆共计 36 名股东发生解禁,累计解禁股数约 1.93 亿股。公司2025 年第三季度营收 4.47 亿元,经调整净利润 0.65 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1551","01057","688796","03858","BK1144","02498","BK1514","BK1149","BK0216","BK1212","BK1116","BK1240","BK1526","03833","00148","06166","02315","BK4585","00826","BK1553","BK1223","BK4588","BK0132","002703","BK1225","BK4213","GDP","00981","VIS","BK1183","01812","BK1614","BK1190","BK1237","BK0264","BK1610","SG9999014674.SGD","BK1163","02579","BK1179","02314","01117","02245","BK1587","BK1170","BK1607","02689","BK1161","02432","09858"],"gpt_icon":1},{"id":"2593344098","title":"百奥赛图-B(02315.HK)涨近20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593344098","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593344098?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:49","pubTimestamp":1766540996,"startTime":"0","endTime":"0","summary":"每经AI快讯,百奥赛图-B(02315.HK)早盘涨近20%,截至发稿涨19.51%,报34.3港元,成交额2273.51万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512243600477911.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"4ce77089c3dfea59728ed7854516af14","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600477911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0216","02315","BK1161","688796"],"gpt_icon":0},{"id":"1128235938","title":"百奥赛图-B获调入港股通标的证券名单,12月24日起生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1128235938","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128235938?lang=zh_cn&edition=full","pubTime":"2025-12-24 08:43","pubTimestamp":1766536980,"startTime":"0","endTime":"0","summary":"12月24日,深交所:港股通标的证券名单调整,调入$百奥赛图-B(02315)$,12月24日起生效。","market":"sh","thumbnail":"https://static.tigerbbs.com/41a3265725dba67c0660b26a189585aa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/41a3265725dba67c0660b26a189585aa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1421e84be9d1e8ccf1d8f45413971ecf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百奥赛图-B获调入港股通标的证券名单,12月24日起生效","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02315","688796"],"gpt_icon":0},{"id":"2591010686","title":"百奥赛图上市第5个交易日跌10.47%创新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2591010686","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591010686?lang=zh_cn&edition=full","pubTime":"2025-12-16 15:43","pubTimestamp":1765870980,"startTime":"0","endTime":"0","summary":"中国经济网北京12月16日讯 百奥赛图(688796.SH)今日盘中最低报50.00元,创上市以来新低。截至今日收盘,该股报50.10元,跌幅10.47%。百奥赛图于2025年12月10日在上交所科创板上市,本次公开 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20251216/c673245244.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20251216/c673245244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2590506663","title":"C百奥(688796)新增【基因】概念","url":"https://stock-news.laohu8.com/highlight/detail?id=2590506663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590506663?lang=zh_cn&edition=full","pubTime":"2025-12-12 20:30","pubTimestamp":1765542626,"startTime":"0","endTime":"0","summary":"证券之星消息,根据市场公开信息整理,12月12日C百奥新增概念。C百奥主营业务:公司基于自主开发的基因编辑技术提供各类创新模式动物以及临床前阶段的医药研发服务,并利用其自主开发的RenMice全人抗体/TCR小鼠平台针对人体内千余个潜在药物靶点进行规模化药物发现与开发,并将有潜力的抗体分子进行对外转让、授权或合作开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200037128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768979329079,"stockEarnings":[{"period":"1week","weight":-0.0944},{"period":"1month","weight":0.2626},{"period":"3month","weight":1.3696},{"period":"ytd","weight":0.2019}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0574},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1409},{"period":"1year","weight":0.2679},{"period":"ytd","weight":0.0365}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥赛图(北京)医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"28549人","perCapita":"1257股","listingDate":"2025-12-10","address":"北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院","registeredCapital":"44689万元","survey":" 百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。","listedPrice":26.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图,688796,百奥赛图股票,百奥赛图股票老虎,百奥赛图股票老虎国际,百奥赛图行情,百奥赛图股票行情,百奥赛图股价,百奥赛图股市,百奥赛图股票价格,百奥赛图股票交易,百奥赛图股票购买,百奥赛图股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}